CATABASIS PHARMACEUTICALS, INC.
ONE KENDALL SQUARE

BUILDING 1400E, SUITE B14202
CAMBRIDGE, MA 02139

 

June 19, 2018

 

Via EDGAR

 

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

 

Re:              Catabasis Pharmaceuticals, Inc.
Registration Statement on Form S-1
File No. 333-225410
Request for Acceleration

 

Ladies and Gentlemen:

 

Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Catabasis Pharmaceuticals, Inc. hereby requests acceleration of the effective date of its Registration Statement on Form S-1 (File No. 333-225410), so that it may become effective at 5:00 p.m. Eastern time on June 19, 2018, or as soon thereafter as practicable.

 

[The remainder of this page is intentionally left blank.]

 



 

Very truly yours,

 

Catabasis Pharmaceuticals, Inc.

 

 

By:

/s/ Deirdre A. Cunnane

 

Name:

Deirdre A. Cunnane

 

Title:

Chief Legal Officer

 

 

[Signature Page to Request for Acceleration]